Joe Poynton has never taken a coding course. Now, after picking up vibe coding, he's an app developer.
Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study ( NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent ...
The deal, reportedly for more than $300 million, demonstrates Anthropic's continued interest in exercising greater control ...
What happens when a scientific problem seems too complex to solve precisely, yet understanding it could reshape how researchers design new materials and medicines? For decades, much of the polymer ...